Improved outcomes, including more organ support-free days, reduced mortality, seen with tocilizumab, sarilumab
Tocilizumab Does Not Improve Outcomes in Severe COVID-19
Tocilizumab plus standard care no better for improving clinical outcomes at 15 days and may increase mortality
Mortality Decreased for COVID-19 ICU Patients Over Time
Mortality decreased from 43.5 to 19.2 percent between first and last 15-day periods; no change seen in other patient factors
For COVID-19 ICU Patients, Death Linked to COVID-19 ICU Strain
Mortality increased when COVID-19 ICU demand was >75 to 100 percent for patients treated in COVID-19 ICU
Men More Likely to Test Positive for SARS-CoV-2, Die From COVID-19
During their hospital course, more men than women experience pulmonary and extrapulmonary complications
Trauma Centers Made New Processes for Optimal Care During COVID-19 Pandemic
Most hospitals designated more beds to the intensive care unit; 50 percent designated an ICU for COVID-19 patients
Tocilizumab Cuts Progression to Ventilation or Death in COVID-19
But death from any cause by day 28 in those hospitalized with COVID-19 pneumonia did not differ for tocilizumab versus placebo
U.S. Hospitals Running Out of ICU Beds for COVID-19 Patients
Hospitals serving more than 100 million Americans had less than 15 percent of intensive care beds still available as of last week
Hospital Mortality Higher for Critically Ill With COVID-19 Versus Flu
Patients with COVID-19 have slower improvement in oxygenation, longer duration of mechanical ventilation, lower rates of extubation